SOLVENTUM CORPORATION (SOLV) Spending and interest coverage
- R&D / revenue · 12 months: Value 8.72%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.01%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 8.72% | Research and development expense / revenue. Period ending 2026-06-30. $725.00M ÷ $8.31B × 100 ≈ 8.72% |
| Stock-based compensation / revenue · 12 months | 2.01% | Share-based compensation / revenue. Period ending 2026-06-30. $167.00M ÷ $8.31B × 100 ≈ 2.01% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 725.00M USD | Research and Development Expense |
| Revenue | 8.31B USD | |
| Stock-based compensation | 167.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.08B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $725.00M | $8.31B | $167.00M | $2.08B | (m) | 8.72% | 2.01% | (m) | (m) |
| 2026-03-31 | $735.00M | $8.26B | $163.00M | $2.11B | (m) | 8.90% | 1.97% | (m) | (m) |
| 2025-12-31 | $739.00M | $8.32B | $161.00M | $2.18B | (m) | 8.88% | 1.93% | (m) | (m) |
| 2025-09-30 | $763.00M | $8.40B | $149.00M | $2.19B | (m) | 9.08% | 1.77% | (m) | (m) |
| 2025-06-30 | $769.00M | $8.39B | $135.00M | $778.00M | (m) | 9.17% | 1.61% | (m) | (m) |
| 2025-03-31 | $773.00M | $8.31B | $157.00M | $807.00M | (m) | 9.30% | 1.89% | (m) | (m) |
| 2024-12-31 | $775.00M | $8.25B | $112.00M | $1.04B | (m) | 9.39% | 1.36% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $758.00M | $8.20B | $39.00M | $1.69B | (m) | 9.25% | 0.48% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $767.00M | $8.13B | $37.00M | $1.69B | (m) | 9.43% | 0.46% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |